CN113913478B - 一种发酵黄色短杆菌产l-缬氨酸的方法 - Google Patents
一种发酵黄色短杆菌产l-缬氨酸的方法 Download PDFInfo
- Publication number
- CN113913478B CN113913478B CN202111425367.4A CN202111425367A CN113913478B CN 113913478 B CN113913478 B CN 113913478B CN 202111425367 A CN202111425367 A CN 202111425367A CN 113913478 B CN113913478 B CN 113913478B
- Authority
- CN
- China
- Prior art keywords
- fermentation
- valine
- brevibacterium flavum
- acetohydroxy acid
- producing
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 title claims abstract description 113
- 229960004295 valine Drugs 0.000 title claims abstract description 58
- 241000319304 [Brevibacterium] flavum Species 0.000 title claims abstract description 48
- 238000004519 manufacturing process Methods 0.000 title claims abstract description 23
- 238000000855 fermentation Methods 0.000 claims abstract description 64
- 230000004151 fermentation Effects 0.000 claims abstract description 56
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 26
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims abstract description 20
- 239000008103 glucose Substances 0.000 claims abstract description 20
- 241000894006 Bacteria Species 0.000 claims abstract description 19
- 239000002253 acid Substances 0.000 claims abstract description 18
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 claims description 22
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 15
- 239000001301 oxygen Substances 0.000 claims description 15
- 229910052760 oxygen Inorganic materials 0.000 claims description 15
- 108010000700 Acetolactate synthase Proteins 0.000 claims description 14
- 239000000843 powder Substances 0.000 claims description 14
- 101150090497 ilvC gene Proteins 0.000 claims description 12
- 229930027917 kanamycin Natural products 0.000 claims description 12
- SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 claims description 12
- 229960000318 kanamycin Drugs 0.000 claims description 12
- 229930182823 kanamycin A Natural products 0.000 claims description 12
- 101100125907 Streptomyces coelicolor (strain ATCC BAA-471 / A3(2) / M145) ilvC1 gene Proteins 0.000 claims description 11
- 229960002685 biotin Drugs 0.000 claims description 11
- 235000020958 biotin Nutrition 0.000 claims description 11
- 239000011616 biotin Substances 0.000 claims description 11
- 229940041514 candida albicans extract Drugs 0.000 claims description 11
- 239000012138 yeast extract Substances 0.000 claims description 11
- 238000009423 ventilation Methods 0.000 claims description 10
- 238000000034 method Methods 0.000 claims description 9
- 239000002773 nucleotide Substances 0.000 claims description 9
- 125000003729 nucleotide group Chemical group 0.000 claims description 9
- 229940088594 vitamin Drugs 0.000 claims description 7
- 229930003231 vitamin Natural products 0.000 claims description 7
- 235000013343 vitamin Nutrition 0.000 claims description 7
- 239000011782 vitamin Substances 0.000 claims description 7
- 150000003722 vitamin derivatives Chemical class 0.000 claims description 7
- 238000010564 aerobic fermentation Methods 0.000 claims description 6
- 239000013530 defoamer Substances 0.000 claims description 4
- 230000014509 gene expression Effects 0.000 claims description 4
- 108091008053 gene clusters Proteins 0.000 claims description 3
- 238000004321 preservation Methods 0.000 claims description 3
- 238000006243 chemical reaction Methods 0.000 abstract description 12
- 239000013604 expression vector Substances 0.000 abstract description 4
- 238000009776 industrial production Methods 0.000 abstract description 4
- 230000009466 transformation Effects 0.000 abstract description 3
- 239000001963 growth medium Substances 0.000 description 16
- 101150091570 gapA gene Proteins 0.000 description 12
- 238000011218 seed culture Methods 0.000 description 12
- 101150039774 GAPA1 gene Proteins 0.000 description 10
- 101100282114 Pseudomonas aeruginosa (strain UCBPP-PA14) gap2 gene Proteins 0.000 description 10
- 101150073818 gap gene Proteins 0.000 description 10
- 239000002609 medium Substances 0.000 description 9
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 8
- 239000012634 fragment Substances 0.000 description 8
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
- LCTONWCANYUPML-UHFFFAOYSA-N Pyruvic acid Chemical compound CC(=O)C(O)=O LCTONWCANYUPML-UHFFFAOYSA-N 0.000 description 6
- 238000006555 catalytic reaction Methods 0.000 description 6
- 208000012788 shakes Diseases 0.000 description 6
- 238000003786 synthesis reaction Methods 0.000 description 6
- 238000012408 PCR amplification Methods 0.000 description 5
- 230000015572 biosynthetic process Effects 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- 239000013598 vector Substances 0.000 description 5
- 239000001888 Peptone Substances 0.000 description 4
- 108010080698 Peptones Proteins 0.000 description 4
- 229930003451 Vitamin B1 Natural products 0.000 description 4
- 239000004202 carbamide Substances 0.000 description 4
- 238000003776 cleavage reaction Methods 0.000 description 4
- 238000011081 inoculation Methods 0.000 description 4
- 235000019319 peptone Nutrition 0.000 description 4
- 239000013612 plasmid Substances 0.000 description 4
- 230000007017 scission Effects 0.000 description 4
- 238000012216 screening Methods 0.000 description 4
- 229960003495 thiamine Drugs 0.000 description 4
- DPJRMOMPQZCRJU-UHFFFAOYSA-M thiamine hydrochloride Chemical compound Cl.[Cl-].CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N DPJRMOMPQZCRJU-UHFFFAOYSA-M 0.000 description 4
- 235000010374 vitamin B1 Nutrition 0.000 description 4
- 239000011691 vitamin B1 Substances 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical group CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical group OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 235000011114 ammonium hydroxide Nutrition 0.000 description 3
- 239000002518 antifoaming agent Substances 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 235000013305 food Nutrition 0.000 description 3
- 238000004108 freeze drying Methods 0.000 description 3
- 230000000813 microbial effect Effects 0.000 description 3
- 229940107700 pyruvic acid Drugs 0.000 description 3
- 239000002994 raw material Substances 0.000 description 3
- JTEYKUFKXGDTEU-UHFFFAOYSA-N 2,3-dihydroxy-3-methylbutanoic acid Chemical compound CC(C)(O)C(O)C(O)=O JTEYKUFKXGDTEU-UHFFFAOYSA-N 0.000 description 2
- QHKABHOOEWYVLI-UHFFFAOYSA-N 3-methyl-2-oxobutanoic acid Chemical compound CC(C)C(=O)C(O)=O QHKABHOOEWYVLI-UHFFFAOYSA-N 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- 241000010804 Caulobacter vibrioides Species 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 241000588724 Escherichia coli Species 0.000 description 2
- 102000004195 Isomerases Human genes 0.000 description 2
- 108090000769 Isomerases Proteins 0.000 description 2
- 239000007836 KH2PO4 Substances 0.000 description 2
- 241000205091 Sulfolobus solfataricus Species 0.000 description 2
- 241001052560 Thallis Species 0.000 description 2
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 2
- 230000003213 activating effect Effects 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 229940024606 amino acid Drugs 0.000 description 2
- 150000005693 branched-chain amino acids Chemical class 0.000 description 2
- 230000000052 comparative effect Effects 0.000 description 2
- -1 compound amino acid Chemical class 0.000 description 2
- 238000010276 construction Methods 0.000 description 2
- 238000012258 culturing Methods 0.000 description 2
- 238000001212 derivatisation Methods 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 239000003797 essential amino acid Substances 0.000 description 2
- 235000020776 essential amino acid Nutrition 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 238000007710 freezing Methods 0.000 description 2
- 230000008014 freezing Effects 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 238000011068 loading method Methods 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 229910000402 monopotassium phosphate Inorganic materials 0.000 description 2
- 235000019796 monopotassium phosphate Nutrition 0.000 description 2
- 238000005457 optimization Methods 0.000 description 2
- 230000037361 pathway Effects 0.000 description 2
- GNSKLFRGEWLPPA-UHFFFAOYSA-M potassium dihydrogen phosphate Chemical compound [K+].OP(O)([O-])=O GNSKLFRGEWLPPA-UHFFFAOYSA-M 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 230000002062 proliferating effect Effects 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 230000001502 supplementing effect Effects 0.000 description 2
- 238000011144 upstream manufacturing Methods 0.000 description 2
- 239000004474 valine Substances 0.000 description 2
- 102100030840 AT-rich interactive domain-containing protein 4B Human genes 0.000 description 1
- 241000203809 Actinomycetales Species 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 108010088278 Branched-chain-amino-acid transaminase Proteins 0.000 description 1
- 241000186216 Corynebacterium Species 0.000 description 1
- 102000012410 DNA Ligases Human genes 0.000 description 1
- 108010061982 DNA Ligases Proteins 0.000 description 1
- 108700016168 Dihydroxy-acid dehydratases Proteins 0.000 description 1
- 101000792935 Homo sapiens AT-rich interactive domain-containing protein 4B Proteins 0.000 description 1
- 125000003580 L-valyl group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C(C([H])([H])[H])(C([H])([H])[H])[H] 0.000 description 1
- 206010049565 Muscle fatigue Diseases 0.000 description 1
- 241000831652 Salinivibrio sharmensis Species 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 239000003674 animal food additive Substances 0.000 description 1
- 101150010487 are gene Proteins 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 230000006696 biosynthetic metabolic pathway Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 235000008429 bread Nutrition 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000030609 dephosphorylation Effects 0.000 description 1
- 238000006209 dephosphorylation reaction Methods 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 238000001976 enzyme digestion Methods 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 238000012262 fermentative production Methods 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 230000034659 glycolysis Effects 0.000 description 1
- 101150043028 ilvD gene Proteins 0.000 description 1
- 101150099953 ilvE gene Proteins 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 230000006799 invasive growth in response to glucose limitation Effects 0.000 description 1
- 101150044508 key gene Proteins 0.000 description 1
- ZPEZUAAEBBHXBT-RZVRUWJTSA-N l-valine l-valine Chemical compound CC(C)[C@H](N)C(O)=O.CC(C)[C@H](N)C(O)=O ZPEZUAAEBBHXBT-RZVRUWJTSA-N 0.000 description 1
- 230000006651 lactation Effects 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000009753 muscle formation Effects 0.000 description 1
- 238000002703 mutagenesis Methods 0.000 description 1
- 231100000350 mutagenesis Toxicity 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000025366 tissue development Effects 0.000 description 1
- 230000001131 transforming effect Effects 0.000 description 1
- 238000000870 ultraviolet spectroscopy Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P13/00—Preparation of nitrogen-containing organic compounds
- C12P13/04—Alpha- or beta- amino acids
- C12P13/08—Lysine; Diaminopimelic acid; Threonine; Valine
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/74—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora
- C12N15/77—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora for Corynebacterium; for Brevibacterium
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/0004—Oxidoreductases (1.)
- C12N9/0006—Oxidoreductases (1.) acting on CH-OH groups as donors (1.1)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/88—Lyases (4.)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y101/00—Oxidoreductases acting on the CH-OH group of donors (1.1)
- C12Y101/01—Oxidoreductases acting on the CH-OH group of donors (1.1) with NAD+ or NADP+ as acceptor (1.1.1)
- C12Y101/01086—Ketol-acid reductoisomerase (1.1.1.86)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y401/00—Carbon-carbon lyases (4.1)
- C12Y401/03—Oxo-acid-lyases (4.1.3)
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02E—REDUCTION OF GREENHOUSE GAS [GHG] EMISSIONS, RELATED TO ENERGY GENERATION, TRANSMISSION OR DISTRIBUTION
- Y02E50/00—Technologies for the production of fuel of non-fossil origin
- Y02E50/10—Biofuels, e.g. bio-diesel
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- Plant Pathology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
本发明公开了一种发酵黄色短杆菌产L‑缬氨酸的方法。本发明将gapA和ilvBNC基因通过表达载体导入黄色短杆菌中,筛选获得高产L‑缬氨酸菌株的黄色短杆菌工程菌;利用该工程菌进行有氧‑厌氧分段发酵,并在厌氧发酵中后期添加VB3以及采用流加葡萄糖的方式,将发酵时间缩短到72h,L‑缬氨酸产率达到了95.00±1.50g/L,转化率达到33%,生产强度为1.32g/L/h,优化了L‑缬氨酸的发酵工艺,极大地提高了菌株的生产力和产酸效率。本发明所得高产L‑缬氨酸菌株,后续改造潜力巨大,且发酵工艺简单易行,成本低廉,适用于工业化生产。
Description
技术领域
本发明涉及一种发酵黄色短杆菌产L-缬氨酸的方法,属于发酵工程技术领域。
背景技术
L-缬氨酸(L-valine),属于分支链氨基酸(branched chain amino acids,BCAA),是人体必需氨基酸之一,分子式C5H11NO2,密度1.316g/cm3,白色结晶或粉末,溶于水,缬氨酸分子是手性分子,根据偏振光的旋转方向分为D型和L型,天然的缬氨酸都为L-缬氨酸。
L-缬氨酸是人体必需氨基酸之一,自身不能合成,必须通过膳食来源来补充,其具有多种生理功能,因此广泛应用于食品、医药、饲料等领域。如在食品行业,添加L-缬氨酸的能量饮料具有促进肌肉形成、减轻肌肉疲劳等作用。在面包糕点中添加L-缬氨酸能极大地提高食品风味、改善口感;在医药行业,L-缬氨酸是制造复合氨基酸药物的重要原料,主要用于血脑、肝脏、代谢缺陷、创伤愈合、营养支持等的治疗,效果显著;在饲料行业中,L-缬氨酸可用于饲料添加剂,在促进乳腺组织发育、改善泌乳功能、调节糖代谢等方面有重要作用。
目前,L-缬氨酸的工业生产方法分为直接提取法、化学合成法和微生物发酵法。微生物发酵法的原料易得、反应条件温和、生产成本低,因此目前世界上L-缬氨酸的工业化生产大多采用微生物发酵法。黄色短杆菌(Brevibacterium flavum)作为食品安全级的微生物,具有易培养、不产孢子等优点,因此是一类重要的工业生产菌株,可用于生产包括L-缬氨酸在内的多种氨基酸。黄色短杆菌是一种无芽孢的、细胞为短小棒状呈八字排列的革兰氏阳性细菌,属于放线菌目棒状杆菌属。
黄色短杆菌中L-缬氨酸的生物合成路径已经明确。葡萄糖经过糖酵解途径生成L-缬氨酸合成的重要前体--丙酮酸,丙酮酸再通过4步反应即可合成L-缬氨酸:首先由ilvBN基因编码的乙酰羟酸合酶将两分子的丙酮酸缩合成2-乙酰羟酸,然后在ilvC基因编码的乙酰羟酸还原异构酶催化下转化为2,3-二羟基异戊酸,再由ilvD基因编码的二羟酸脱水酶将2,3-二羟基异戊酸脱水形成2-酮基异戊酸,最后ilvE基因编码的支链氨基酸转氨酶将2-酮基异戊酸转化成L-缬氨酸。胞内积累的L-缬氨酸由brnFE编码的转运蛋白复合体BrnFE转运至胞外。
徐庆阳等人以黄色短杆菌XV0505为生产菌株,通过优化发酵条件,10L罐发酵72h,L-缬氨酸产量达到53.4g/L。张伟国等人以L-缬氨酸产生菌黄色短杆菌XQ-2为出发菌株,经诱变处理及定向筛选,获得一株L-缬氨酸高产菌黄色短杆菌XQ-8,其摇瓶发酵72h后,L-缬氨酸产量达64-66g/L。专利201910349690.4“一株产L-缬氨酸的黄色短杆菌及其应用”经筛选获得一株高产L-缬氨酸的黄色短杆菌B.flavum FMME447,通过对培养基进行优化,发酵90h,其产率达到了80-90g/L。
其中,专利201910349690.4中L-缬氨酸能够达到较高的产量,但是其中培养基的成本相对较高,且发酵时间相对较长,发明人预更换培养基,并采用一种有氧与厌氧联合发酵的方法进行发酵,但是采用201910349690.4中的菌株进行发酵时,72h产量仅达到31±0.5g/L,转化率和生产强度都很低。
发明内容
为解决上述技术问题,本发明提供一种发酵黄色短杆菌产L-缬氨酸的方法,一方面对菌株进行了改造,在产L-缬氨酸的黄色短杆菌中过表达乙酰羟酸合酶ilvBN和乙酰羟酸还原异构酶ilvC(乙酰羟酸合酶ilvBN和乙酰羟酸还原异构酶ilvC的编码基因为基因簇ilvBNC),并采用强启动子gapA启动表达关键基因ilvBNC,获得能够高表达L-缬氨酸的黄色短杆菌,另一方面对发酵工艺进行优化,进一步提升L-缬氨酸的产量、转化率及生产强度。
本发明的第一个目的是提供一种发酵黄色短杆菌产L-缬氨酸的方法,所述方法采用黄色短杆菌工程菌为发酵菌株,按照如下步骤进行发酵:
S1、制备黄色短杆菌工程菌种子液;
S2、将所述的黄色短杆菌工程菌种子液接种至发酵培养基中进行有氧发酵,并采用两阶段溶氧控制有氧发酵过程;
其中,所述的两阶段溶氧控制为:阶段一、发酵至OD在10-12时,溶氧降为0,阶段二、OD610达到45-50时,停止通气,并降低转速;
S3、至S2步骤中残糖接近0时,转为厌氧发酵至发酵结束,在厌氧发酵过程中,流加葡萄糖控制发酵液中葡萄糖的质量百分比浓度为7%-9%,并在厌氧发酵到15-30h时添加VB3;
其中,所述的黄色短杆菌工程菌是在产L-缬氨酸的黄色短杆菌中过表达乙酰羟酸合酶ilvBN和乙酰羟酸还原异构酶ilvC,并采用强启动子gapA启动乙酰羟酸合酶ilvBN编码基因和乙酰羟酸还原异构酶ilvC编码基因表达。
进一步地,所述的发酵培养基由以下组分构成:(NH4)2SO4 8-15g/L,KH2PO4 1-1.5g/L,K2HPO4 1-1.5g/L,MgSO4·7H2O 0.5-0.8g/L,酵母浸出粉3-6g/L,FeSO4·7H2O 0.2-20mg/L,MnSO4·H2O 4-20mg/L,生物素0.02-0.2mg/L,维生素B1 0.2-2mg/L,消泡剂0.5-1mL/L,葡萄糖60-100g/L,卡那霉素30-60mg/L,VB3 10-20mg/L。
进一步地,有氧发酵的初始发酵条件为:温度30-33℃,pH 7.5±0.5,罐压0.02-0.05mpa,风量0.3-0.5m3/h,转速280-320rpm,溶氧不低于10%。
进一步地,在溶氧控制的阶段二中,OD610达到45-50时,转速降低至100-200rpm。
进一步地,在厌氧发酵时,所述的VB3添加浓度为10-20mg/L。
进一步地,厌氧发酵的条件为:温度30-33℃,pH 7.5±0.5,转速100-200rpm,罐压0mpa,不通风。
进一步地,所述的产L-缬氨酸的黄色短杆菌的保藏编号为CCTCC NO:M 2019053。
进一步地,所述的强启动子gapA的核苷酸序列如SEQ ID NO.1所示,所述的乙酰羟酸合酶ilvBN编码基因和所述的乙酰羟酸还原异构酶ilvC编码基因组成的基因簇ilvBNC的核苷酸序列如SEQ ID NO.2所示。
进一步地,将所述的黄色短杆菌工程菌种子液接种至发酵培养基中的接种量为质量浓度8-12%。
进一步地,所述的种子液制备包括斜面培养、一级摇瓶种子培养和二级种子培养。
进一步地,所述的斜面培养为将冻干管中的菌体划线活化于斜面培养基,在30-33℃恒温培养20-30h。
进一步地,所述的一级摇瓶种子培养为将斜面培养得到的菌株接种于一级种子培养基,100-140rpm,30-33℃恒温培养6-8h,OD610*25在8.0-10.0之间,得到一级种子液。
进一步地,所述的二级摇瓶种子培养为将所述一级种子液按1-3%的接种量接种于二级培养基,10-1400rpm,30-33℃恒温培养6-8h,4-5.5h时加入20-30%的氨水维持pH在7.5±0.1,OD610*25在8.0-12.0之间,得到所述的种子液。
进一步地,所述一级种子培养基由以下组分构成:尿素1-3g/L,(NH4)2SO4 6-10g/L,KH2PO4 0.5-0.8g/L,K2HPO4 0.5-0.8g/L,MgSO4·7H2O 0.5-0.8g/L,酵母浸出粉(OXOID)1-3g/L,蛋白胨(OXOID)7-9g/L,FeSO4·7H2O 4-10mg/L,MnSO4·H2O 4-10mg/L,生物素0.25-0.5mg/L,维生素B1 0.25-0.5mg/L,葡萄糖20-50g/L,卡那霉素30-60mg/L;pH 7.5±0.1。
进一步地,所述二级种子培养基由以下组分构成:(NH4)2SO4 8-10g/L,KH2PO4 0.8-1.0g/L,K2HPO4 0.8-1.0g/L,MgSO4·7H2O 0.5-0.8g/L,酵母浸出粉3-6g/L,FeSO4·7H2O20-40mg/L,MnSO4·H2O 4-10mg/L,生物素0.02-0.2mg/L,维生素B1 0.2-2mg/L,消泡剂0.5-1mL/L,葡萄糖20-50g/L,卡那霉素30-60mg/L,VB3 10-20mg/L;pH 7.5±0.1。
本发明的第二个目的是提供一种黄色短杆菌工程菌,所述的黄色短杆菌工程菌是在保藏编号为CCTCC NO:M 2019053的黄色短杆菌中过表达乙酰羟酸合酶ilvBN和乙酰羟酸还原异构酶ilvC,并采用强启动子gapA启动乙酰羟酸合酶ilvBN编码基因和乙酰羟酸还原异构酶ilvC编码基因表达;其中,强启动子gapA的核苷酸序列如SEQ ID NO.1所示,乙酰羟酸合酶ilvBN编码基因和乙酰羟酸还原异构酶ilvC编码基因组成的基因簇ilvBNC的核苷酸序列如SEQ ID NO.2所示。
本发明的第三个目的是提供所述的黄色短杆菌工程菌的构建方法,包括如下步骤:
(1)将gapA和ilvBNC基因片段连接至表达载体上,得到重组载体;
(2)将所述重组载体转化至宿主菌中,筛选获得所述黄色短杆菌工程菌。
本发明的上述技术方案相比现有技术具有以下优点:
本发明利用L-缬氨酸合成途径上的两个关键基因gapA和ilvBNC,将其导入到黄色短杆菌内,使得黄色短杆菌内过表达合成L-缬氨酸,有效提高了L-缬氨酸的产量,最终获得了一株高产L-缬氨酸的黄色短杆菌工程菌;
通过采用有氧-厌氧分段发酵,以及厌氧发酵期间进行VB3补料并采用流加葡萄糖的方式,进一步优化了L-缬氨酸的发酵工艺,极大地提高了菌株的生产力和产酸效率,并将发酵时间缩短到了72h,L-缬氨酸产量达到了95.00±1.50g/L,转化率达到了33%-35%,生产强度为1.32-1.34g/L/h;
本发明所得工程菌后续改造潜力巨大,且发酵方法操作简便、设备要求低,发酵时间短,生产成本低,可进行自动化控制,适用于工业化规模生产。
附图说明:
图1是本发明黄色短杆菌FMME 33的发酵过程曲线图。
图2是本发明黄色短杆菌FMME 33的菌落形态图。
具体实施方式
下面结合具体实施例对本发明作进一步说明,以使本领域的技术人员可以更好地理解本发明并能予以实施,但所举实施例不作为对本发明的限定。
本发明实施例所采用的试剂和药品均为市售原料。
本发明实施例的培养基类型及组成:
(1)斜面培养基:尿素2.5g/L,(NH4)2SO4 7g/L,KH2PO4 0.5g/L,K2HPO4 0.5g/L,MgSO4·7H2O 0.5g/L,酵母浸出粉(OXOID)2g/L,蛋白胨(OXOID)7g/L,FeSO4·7H2O 6mg/L,MnSO4·H2O 4mg/L,生物素0.2mg/L,维生素B1 0.2mg/L,琼脂粉15g/L,葡萄糖40g/L,卡那霉素50mg/L,pH为7.5±0.1;
(2)一级种子培养基:尿素2.5g/L,(NH4)2SO4 7g/L,KH2PO4 0.5g/L,K2HPO4 0.5g/L,MgSO4·7H2O 0.5g/L,酵母浸出粉(OXOID)2g/L,蛋白胨(OXOID)7g/L,FeSO4·7H2O 6mg/L,MnSO4·H2O 4mg/L,生物素0.2mg/L,维生素B1 0.2mg/L,葡萄糖40g/L,卡那霉素50mg/L,pH为7.5±0.1。
(3)二级种子培养基:(NH4)2SO4 10g/L,KH2PO4 0.8g/L,K2HPO4 0.8g/L,MgSO4·7H2O 0.5g/L,酵母浸出粉3g/L,FeSO4·7H2O 20mg/L,MnSO4·H2O 4mg/L,生物素0.02mg/L,维生素B1 2mg/L,消泡剂0.5mL/L,葡萄糖40g/L,卡那霉素50mg/L,VB3 13mg/L,pH为7.5±0.1。
序列表中相关核苷酸序列信息:
SEQ ID NO.1序列信息为gapA基因的核苷酸序列;SEQ ID NO.2序列信息为ilvBNC基因的核苷酸序列。
菌体浓度测定:
取发酵液适当稀释,使用紫外-可见分光光度计在波长为610nm下测定OD610值。
L-缬氨酸含量的测定:
(1)发酵液预处理:取发酵液12000rpm离心10min后取上清,用0.22μm滤膜过滤;
(2)高效液相色谱法(HPLC)检测发酵液中L-缬氨酸含量:流动相A为0.01mol/LKH2PO4溶液,用KOH调pH至5.3;流动相B为乙腈、甲醇与流动相A按5:3:1的体积比混合后用乙酸调pH至5.3。色谱柱为Aglient ZORBAX SB-Aq 250×4.6mm,5μm。利用柱前在线衍生方法,衍生剂为OPA,柱温:35℃,流速为1.0mL/min进行梯度洗脱,检测波长:UV 254nm;FLD:激发波长330nm/发射波长465nm。。
实施例1:B.flavum FMME 33的构建
为了在黄色短杆菌内过表达合成路径上的关键基因,故以B.flavum FMME 447的基因组为出发菌株,将两个基因片段导入菌体中,分别是强启动子gapA和合成路径关键基因ilvBNC。
对于gapA片段,设计gapA-F和gapA-R引物,对于ilvBNC片段,设计ilvBNC-F和ilvBNC-R引物。
引物序列信息:
gapA-F:5’-GAAGATCTGAAGATTCCTGA-3’;(SEQ ID NO.3)
gapA-R:5’-TCATGGTGTGTCTCCTCTAA-3’;(SEQ ID NO.4)
其中上游引物gapA-F带有BglII酶切位点,酶切位点如下划线序列,下游引物gapA-R带有NcoI和BspHI同尾酶酶切位点,酶切位点如下划线序列。
引物序列信息:
ilvBNC-F:5’-CCATGAATGTGGCAGCTTCT-3’;(SEQ ID NO.5)
ilvBNC-R:5’-AGATCTTTAAGCGGTTTCTG-3’;(SEQ ID NO.6)
其中上游引物ilvBNC-F带有NcoI和BspHI同尾酶酶切位点,酶切位点如下划线序列,下游引物ilvBNC-R带有BglII酶切位点,酶切位点如下划线序列。
PCR分别扩增gapA和ilvBNC基因,进行PCR扩增后得到其扩增片段,扩增反应体系如表1所示,反应条件如表2和表3所示。按照购自上海生工的PCR产物凝胶回收试剂盒,PCR扩增产物跑电泳确定目的条带后切胶回收进行纯化。
表1 PCR扩增反应体系
表2 gapA基因PCR扩增反应条件
表3 ilvBNC基因PCR扩增反应条件
以穿梭质粒pZ81-3为载体,采用BglII单酶切并用去磷酸化酶FastAP酶进行末端去磷酸化得到载体片段,将上述纯化回收的两段基因片段和载体片段采用T4 DNALigase进行连接得到表达载体,连接体系如表4所示;转化感受态的JM109细胞,采用质粒提取试剂盒进行重组质粒的抽提和验证,进而确定重组质粒。
表4连接体系
将构建成功的外源表达载体电击转化B.flavum FMME 447,采用含卡那霉素抗性平板进行筛选,对培养基上长出的转化子进行验证,获得目的菌株,将其命名为Brevibacterium flavum FMME 33,菌落图如图2所示。
实施例2:B.flavum FMME 33发酵生产L-缬氨酸
上罐流程:冷冻甘油管→活化斜面→摇瓶一级种子→发酵增殖罐→厌氧生物催化。
(1)斜面培养:把冻干管中的菌体划线活化于新鲜斜面培养基,30℃恒温培养24h左右;
(2)一级摇瓶种子培养:接一只活化斜面于装有100mL一级种子培养基的500mL三角瓶中,往复式摇床100rpm,30℃恒温培养6-8h左右,OD610*25在6.0-8.0之间即可;
(3)发酵罐发酵:接种量为8%,发酵初始条件:温度30℃,pH 7.5,罐压0.02mpa,风量0.5m3/h,转速300rpm,溶氧不低于10%;两阶段溶氧控制:维持初始条件,当OD在8-10时,溶氧降为0,维持条件不变,流加氨水维持pH在7.5±0.1,当OD610达到45-50时,停止通气,转速降为100rpm,其他条件不变,维持2h左右;当残糖降至接近0时,厌氧催化开始:厌氧催化条件温度33℃,pH 7.5,转速150rpm,罐压0,不通风,流加葡萄糖至9%,每2h检测残糖,残糖降至1%以下,发酵结束。
结果表明,采用本实施例的方法利用B.flavum FMME 33发酵生产L-缬氨酸,经过72h发酵,L-缬氨酸产量可以达到54.16g/L。而采用201910349690.4中的菌株B.flavumFMME 447进行发酵时,72h产量仅达到31±0.5g/L。
本实施例所用发酵培养基由以下组分构成:(NH4)2SO4 8g/L,KH2PO4 0.8g/L,K2HPO4 0.8g/L,MgSO4·7H2O 0.4g/L,酵母浸出粉3g/L,FeSO4·7H2O 20mg/L,MnSO4·H2O4mg/L,生物素0.02mg/L,维生素B1 2mg/L,消泡剂0.5mL/L,葡萄糖60g/L,卡那霉素50mg/L,pH为7.5±0.1。
实施例3:B.flavum FMME 33生产L-缬氨酸的发酵优化
上罐流程:冷冻甘油管→活化斜面→摇瓶一级种子→摇瓶二级种子→发酵增殖罐→厌氧生物催化。
(1)斜面培养:把冻干管中的菌体划线活化于新鲜斜面培养基,30℃恒温培养24h左右;
(2)一级摇瓶种子培养:接一只活化斜面于装有100mL一级种子培养基的500mL三角瓶中,往复式摇床120rpm,30℃恒温培养6-8h左右,OD610*25在8.0-10.0之间即可;
(3)二级摇瓶种子培养:将一级种子按2%的接种量接种于装有100mL培养基的500mL三角瓶中,往复式摇床120rpm,30℃恒温培养6-8h左右,并在4.5h时加入100μL 25%的氨水,OD610*25(净值)在8.0-12.0之间即可;
(4)发酵罐发酵:接种量为10%,发酵初始条件:温度30℃,pH 7.5,罐压0.02mpa,风量0.5m3/h,转速320rpm,溶氧不低于10%。两阶段溶氧控制:维持初始条件,当OD在10-12时,溶氧降为0,维持条件不变。流加氨水维持pH在7.5±0.1。当OD610达到45-50时,停止通气,转速降为100rpm,其他条件不变,维持2h左右当残糖降至接近0时,厌氧催化开始;厌氧催化条件温度33℃,pH 7.5,转速150rpm,罐压0,不通风。流加葡萄糖至9%,每2h检测残糖,残糖降至1%以下,发酵结束;
(5)补料:发酵厌氧催化培养到24h,补小料VB3 10mg/L;发酵生产L-缬氨酸的结果如图1所示。
本实施例中,
一级种子培养基由以下组分构成:尿素2.5g/L,(NH4)2SO4 7g/L,KH2PO4 0.5g/L,K2HPO4 0.5g/L,MgSO4·7H2O 0.5g/L,酵母浸出粉(OXOID)2g/L,蛋白胨(OXOID)7g/L,FeSO4·7H2O 6mg/L,MnSO4·H2O 4mg/L,生物素0.2mg/L,维生素B1 0.2mg/L,葡萄糖40g/L,卡那霉素50mg/L,pH为7.5±0.1;
二级种子培养基由以下组分构成:(NH4)2SO4 10g/L,KH2PO4 0.8g/L,K2HPO4 0.8g/L,MgSO4·7H2O 0.5g/L,酵母浸出粉3g/L,FeSO4·7H2O 20mg/L,MnSO4·H2O 4mg/L,生物素0.02mg/L,维生素B1 2mg/L,消泡剂0.5mL/L,葡萄糖40g/L,卡那霉素50mg/L,VB3 13mg/L,pH为7.5±0.1;
发酵培养基由以下组分构成:(NH4)2SO4 10g/L,KH2PO4 1g/L,K2HPO4 1g/L,MgSO4·7H2O 0.5g/L,酵母浸出粉3g/L,FeSO4·7H2O 20mg/L,MnSO4·H2O 4mg/L,生物素0.02mg/L,维生素B1 2mg/L,消泡剂0.5mL/L,葡萄糖90g/L,卡那霉素50mg/L,小料VB3 13mg/L,pH为7.5±0.1。
图1的HPLC检测结果表明,采用本实施例B.flavum FMME 33发酵生产L-缬氨酸的方法,经过72h发酵,L-缬氨酸产量可以达到95.00±1.50g/L,产量较优化前提高了75.41%,转化率达到33%,生产强度为1.32g/L/h。
对比例1-6:
在实施例1的基础上,将合成路径关键基因ilvBNC替换为来源于Escherichiacoli、Caulobacter vibrioides或Saccharolobus solfataricus的乙酰羟酸合酶或乙酰羟酸还原异构酶编码的基因对菌株进行改造。
研究结果发现对比例1-6采用来源于Escherichia coli、Caulobactervibrioides或Saccharolobus solfataricus的乙酰羟酸合酶或乙酰羟酸还原异构酶编码的基因所制备的工程菌生产L-缬氨酸的效率明显低于本实施例1制备的工程菌B.flavumFMME 33。
以上所述实施例仅是为充分说明本发明而所举的较佳的实施例,本发明的保护范围不限于此。本技术领域的技术人员在本发明基础上所作的等同替代或变换,均在本发明的保护范围之内。本发明的保护范围以权利要求书为准。
序列表
<110> 江南大学
<120> 一种发酵黄色短杆菌产L-缬氨酸的方法
<160> 6
<170> SIPOSequenceListing 1.0
<210> 1
<211> 548
<212> DNA
<213> (人工序列)
<400> 1
agatctgaag attcctgata caaattctgt tgtgacggaa gatttgttgg aagaaatcta 60
gtcgctcgtc tcataaaaac gaccgagcct attgggatta ccattgaagc cagtgtgagt 120
tgcatcacac tggcttcaaa tctgagactt tactttgtgg atcacggggg tgtagtgcaa 180
ttcataatta gccccattcg ggggagcaga tcgcggcgcg aacgatttca ggttcgttcc 240
ctgcaaaaac tatttagcgc aagtgttgga aatgcccccg tctggggtca atgtctattt 300
ttgaatgtgt ttgtatgatt ttgaatccgc tgcaaaatct ttgtttcccc gctaaagttg 360
gggacaggtt gacacggagt tgactcgacg aattatccaa tgtgagtagg tttggtgcgt 420
gagttggaaa atttcgccat actcgccctt gggttctgtc agctcaagaa ttcttgagtg 480
accgatgctc tgattgacct aactgcttga cacattgcat ttcctacaat ctttagagga 540
gacacacc 548
<210> 2
<211> 3608
<212> DNA
<213> (人工序列)
<400> 2
atgaatgtgg cagcttctca acagcccact cccgccacgg ttgcaagccg tggtcgatcc 60
gccgcccctg agcggatgac aggtgcacag gcaattgttc gatcgctcga ggagcttaac 120
gccgacatcg tgttcggtat tcctggtggt gcggtgctac cggtgtatga cccgctctat 180
tcctccacaa aggtgcgcca cgtcttggtg cgccacgtct tggtgcgcca cgagcagggc 240
gcaggccacg cagcaaccgg ctacgcgcag gttactggac gcgttggcgt ctgcattgca 300
acctctggcc caggagcaac caacttggtt accccaatcg ctgatgcaaa cttggactcc 360
gttcccatgg ttgccatcac cggccaggtc ggaagtggcc tgctgggtac cgacgctttc 420
caggaagccg atatccgcgg catcaccatg ccagtgacca agcacaactt catggtcacc 480
gaccccaacg acattccaca ggcattggct gaggcattcc acctcgcgat tactggtcgc 540
cctggccctg ttctggtgga tattcctaag gatgtccaga acgctgaatt ggatttcgtc 600
tggccaccaa agatcgacct gccaggctac cgcccagttt caacaccaca tgctcgccag 660
atcgagcagg cagtcaagct gatcggtgag gccaagaagc ccgtccttta cgttggaggc 720
ggcgttatca aggctgacgc acacgaagag cttcgtgcgt tcgctgagta caccggcatc 780
ccagttgtca ccaccttgat ggctttgggt actttcccag agtctcacga gctgcacatg 840
ggtatgccag gcatgcatgg cactgtgtcc gctgttggtg cactgcagcg cagcgacctg 900
ctgattgcta tcggctcccg ctttgatgac cgcgtcaccg gtgacgttga caccttcgcg 960
cctgacgcca agatcattca cgccgatatg atcctgccga aatcggaaag atcaagcagg 1020
ttgaggttcc aatcgtgggc gatgcccgcg aagttcttgc tcgtctgctg gaaaccacca 1080
aggcaagcaa ggcagagacc gaggacatct ccgagtgggt tgactacctc aagggcctca 1140
aggcacgttt cccacgtggc tacgacgagc agccaggcga tctgctggca ccacagtttg 1200
tcattgaaac cctgtccaag gaagttggcc ccgacgcaat ttactgcgcc ggcgtcggac 1260
agcaccaaat gtgggcagct cagttcgttg actttgaaaa gccacgcacc tggctcaact 1320
ccggtggact gggcaccatg ggctacgcag ttcctgcggc ccttggagca aaggctggcg 1380
cacctgacaa ggaagtctgg gctatcgacg gcgacggctg tttccagatg accaaccagg 1440
aactcaccac cgccgcagtt gaaggtttcc ccattaagat cgcactaatc aacaacggaa 1500
acctgggcat ggttcgccaa tggcagaccc tattctatga aggacggtac tcaaatacta 1560
aacttcgtaa ccagggcgag tacatgcccg actttgttgc cctttctgag ggacttggct 1620
gtgttgccat ccgcgtcacc aaagcggagg aagtactgcc agccatccaa aaggctcgag 1680
aaatcaacga ccgcccagta gtcatcgact tcatcgtcgg tgaagacgca caggtatggc 1740
caatggtgtc tgctggatca tccaactccg atatccagta cgcactcgga ttgcgcccat 1800
tctttgacgg cgacgaatca gctgcagaag accctgcaga cattcatgct tccgttgatt 1860
cgaccgaggc ctaaggagag acccaagatg gctaattctg acgtcacccg ccacatcctg 1920
tccgtactcg ttcaggacgt agacggaatc atttcccgcg tatcaggtat gttcacccga 1980
cgcgcattca acctcgtgtc cctcgtgtct gcaaagaccg aaacacacgg catcaaccgc 2040
atcacggttg ttgtcgacgc cgacgagctc aacattgagc agatcaccaa gcagctcaac 2100
aagctgatcc cggtgctcaa agtcgtgcga cttgatgaag agaccactat cgcccgcgca 2160
atcatgctgg ttaaggtctc tgcggacagc accaaccgtc cgcagatcgt cgacgccgcg 2220
aacatcttcc gcgcccgagt cgtcgacgtg gctccagact ctgtggttat tgaatccaca 2280
ggcaccccag gcaagctccg cgctctgctt gatgtgatgg aaccattcgg aatccgcgaa 2340
ctgatccaat ccgaacagat tgcactcaac cgcggtccga agaccatggc tccggccaag 2400
atctaaacag caattaatct gattgcacct gctgcataaa tgtgactagt caaacaccgt 2460
ctaattacat gtgtgtggta gaacaataat gtagttgtct gcccaaccga gtgacactcc 2520
cacgatttac agtgggggca gacatctttt caccaaaatt tttacgaaag gcgagatttt 2580
ctcccatggc tattgaactg ctttatgatg ctgacgctga cctctccttg atccagggcc 2640
gtaaggttgc catcgttggc tacggctccc agggccacgc acacggccag aacctccgcg 2700
attctggcgt tgaggttgtc attggtgagt tcgagggctc caagtccgca gagaaggcaa 2760
aggaagcagg cttcgaagtc aagaccaccg ctgaggctgc agcttgggct gacgtcatca 2820
tgctcctggc tccagacacc tcccaggcag aaatcttcac caacgacatc gagccaaacc 2880
tgaacgcagg cgacgcactg ctgttcggcc acggcctgaa cattcacttc gacctgatca 2940
agccagctga cgacatcatc gttggcatgg ttgcgccaaa gggcccaggc cacttggttc 3000
gccgtcagtt cgttgatggc aagggtgttc cttgcctcat cgcagtcgac caggacccaa 3060
ccggaaccgc acaggctctg accctgtcct acgcagcagc aatcggtggc gcacgcgcag 3120
gcgttatccc aaccaccttc gaagctgaga ccgtcaccga cctcttcggc gagcaggctg 3180
ttctctgcgg tggcaccgag gaactggtca aggttggctt cgaggttctc accgaagctg 3240
gctacgagcc agagatggca tacttcgagg ttcttcacga gctcaagctc atcgttgacc 3300
tcatgttcga aggtggcatc agcaacatga actactctgt ttctgacacc gctgagttcg 3360
gtggctacct ctccggccca cgcgtcatcg atgcagacac caagtcccgc atgaaggaca 3420
tcctgaccga tatccaggac ggcaccttca ccaagcgcct catcgcaaac gttgagaacg 3480
gcaacaccga gcttgagggt cttcgtgctt cctacaacaa ccacccaatc gaggagaccg 3540
gcgctaagct ccgcgacctc atgagctggg tcaaggttga cgctcgcgca gaaaccgctt 3600
aaagatct 3608
<210> 3
<211> 20
<212> DNA
<213> (人工序列)
<400> 3
gaagatctga agattcctga 20
<210> 4
<211> 20
<212> DNA
<213> (人工序列)
<400> 4
tcatggtgtg tctcctctaa 20
<210> 5
<211> 20
<212> DNA
<213> (人工序列)
<400> 5
ccatgaatgt ggcagcttct 20
<210> 6
<211> 20
<212> DNA
<213> (人工序列)
<400> 6
agatctttaa gcggtttctg 20
Claims (3)
1.一种发酵黄色短杆菌产L-缬氨酸的方法,其特征在于,所述方法采用黄色短杆菌工程菌为发酵菌株,按照如下步骤进行发酵:
S1、制备黄色短杆菌工程菌种子液;
S2、将所述的黄色短杆菌工程菌种子液接种至发酵培养基中进行有氧发酵,并采用两阶段溶氧控制有氧发酵过程;
其中,所述的两阶段溶氧控制为:阶段一、发酵至OD在10-12时,溶氧降为0,阶段二、OD610达到45-50时,停止通气,并降低转速;
S3、至S2步骤中残糖接近0时,转为厌氧发酵至发酵结束,在厌氧发酵过程中,流加葡萄糖控制发酵液中葡萄糖的质量百分比浓度为7%-9%,并在厌氧发酵到15-30 h时添加VB3;
其中,所述的黄色短杆菌工程菌是在产L-缬氨酸的黄色短杆菌中过表达乙酰羟酸合酶ilvBN和乙酰羟酸还原异构酶ilvC,并采用强启动子gapA启动乙酰羟酸合酶ilvBN编码基因和乙酰羟酸还原异构酶ilvC编码基因表达;
所述的发酵培养基由以下组分构成:(NH4)2SO4 8-15 g/L,KH2PO4 1-1.5 g/L,K2HPO4 1-1.5 g/L,MgSO4·7H2O 0.5-0.8 g/L,酵母浸出粉3-6 g/L,FeSO4·7H2O 0.2-20 mg/L,MnSO4·H2O 4-20 mg/L,生物素 0.02-0.2 mg/L,维生素B1 0.2-2 mg/L,消泡剂 0.5-1 mL/L,葡萄糖 60-100 g/L,卡那霉素 30-60 mg/L,VB3 10-20 mg/L;
有氧发酵的初始发酵条件为:温度30-33 ℃,pH 7.5±0.5,罐压0.02-0.05 mpa,风量0.3-0.5 m3/h,转速280-320 rpm,溶氧不低于10%;
厌氧发酵的条件为:温度30-33 ℃,pH 7.5±0.5,转速100-200 rpm,罐压0 mpa,不通风;
所述的产L-缬氨酸的黄色短杆菌的保藏编号为CCTCC NO:M 2019053;
所述的强启动子gapA的核苷酸序列如SEQ ID NO.1所示,所述的乙酰羟酸合酶ilvBN编码基因和所述的乙酰羟酸还原异构酶ilvC编码基因组成的基因簇ilvBNC的核苷酸序列如SEQ ID NO.2所示。
2.根据权利要求1所述的方法,其特征在于,在溶氧控制的阶段二中,OD610达到45-50时,转速降低至100-200 rpm。
3.根据权利要求1所述的方法,其特征在于,在厌氧发酵时,所述的VB3添加浓度为10-20mg/L。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202111425367.4A CN113913478B (zh) | 2021-11-26 | 2021-11-26 | 一种发酵黄色短杆菌产l-缬氨酸的方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202111425367.4A CN113913478B (zh) | 2021-11-26 | 2021-11-26 | 一种发酵黄色短杆菌产l-缬氨酸的方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN113913478A CN113913478A (zh) | 2022-01-11 |
CN113913478B true CN113913478B (zh) | 2023-06-02 |
Family
ID=79248078
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202111425367.4A Active CN113913478B (zh) | 2021-11-26 | 2021-11-26 | 一种发酵黄色短杆菌产l-缬氨酸的方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN113913478B (zh) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN116333956B (zh) * | 2023-03-09 | 2024-07-26 | 江南大学 | 一种谷氨酸棒状杆菌及采用谷氨酸棒状杆菌发酵生产l-缬氨酸的方法 |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2002055711A2 (de) * | 2001-01-12 | 2002-07-18 | Forschungszentrum Jülich GmbH | Verfahren zur fermentativen herstellung von pantothensäure |
CN101939412A (zh) * | 2007-09-04 | 2011-01-05 | 味之素株式会社 | 生产氨基酸的微生物以及氨基酸的生产方法 |
CN103642766A (zh) * | 2013-07-02 | 2014-03-19 | 廊坊梅花生物技术开发有限公司 | 蛋白、dna分子、含有该dna的转化宿主及该转化宿主用于生产l-缬氨酸的方法 |
CN104561074A (zh) * | 2014-12-30 | 2015-04-29 | 福建师范大学 | 一株高产l-缬氨酸工程菌的构建及其应用 |
CN110643547A (zh) * | 2019-11-07 | 2020-01-03 | 巴彦淖尔华恒生物科技有限公司 | 一种产l-缬氨酸的黄色短杆菌及利用该菌生产l-缬氨酸的方法 |
CN110982768A (zh) * | 2019-12-23 | 2020-04-10 | 江南大学 | 强化丙酮酸合成l-亮氨酸能力的重组谷氨酸棒杆菌及应用 |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE102004046933A1 (de) * | 2004-09-28 | 2006-03-30 | Forschungszentrum Jülich GmbH | Verfahren zur fermentativen Herstellung von L-Valin sowie dafür geeigneter Mikroorganismus |
-
2021
- 2021-11-26 CN CN202111425367.4A patent/CN113913478B/zh active Active
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2002055711A2 (de) * | 2001-01-12 | 2002-07-18 | Forschungszentrum Jülich GmbH | Verfahren zur fermentativen herstellung von pantothensäure |
CN101939412A (zh) * | 2007-09-04 | 2011-01-05 | 味之素株式会社 | 生产氨基酸的微生物以及氨基酸的生产方法 |
CN103642766A (zh) * | 2013-07-02 | 2014-03-19 | 廊坊梅花生物技术开发有限公司 | 蛋白、dna分子、含有该dna的转化宿主及该转化宿主用于生产l-缬氨酸的方法 |
CN104561074A (zh) * | 2014-12-30 | 2015-04-29 | 福建师范大学 | 一株高产l-缬氨酸工程菌的构建及其应用 |
CN110643547A (zh) * | 2019-11-07 | 2020-01-03 | 巴彦淖尔华恒生物科技有限公司 | 一种产l-缬氨酸的黄色短杆菌及利用该菌生产l-缬氨酸的方法 |
CN110982768A (zh) * | 2019-12-23 | 2020-04-10 | 江南大学 | 强化丙酮酸合成l-亮氨酸能力的重组谷氨酸棒杆菌及应用 |
Also Published As
Publication number | Publication date |
---|---|
CN113913478A (zh) | 2022-01-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN110607268B (zh) | 一株高产l-缬氨酸的基因工程菌及发酵生产l-缬氨酸方法 | |
CN116333956B (zh) | 一种谷氨酸棒状杆菌及采用谷氨酸棒状杆菌发酵生产l-缬氨酸的方法 | |
CN112961815B (zh) | 一种高产四氢嘧啶的基因工程菌及其应用 | |
CN113913478B (zh) | 一种发酵黄色短杆菌产l-缬氨酸的方法 | |
CN117327635A (zh) | 一种高效生物合成羟基酪醇的重组基因工程菌 | |
CN117844728B (zh) | 一种l-缬氨酸生产菌株及其构建方法与应用 | |
CN116590209A (zh) | 一种产d-泛酸的基因工程菌、构建方法及应用 | |
CN114480359A (zh) | 一种高密度发酵生产阿洛酮糖3-差向异构酶的方法 | |
CN111944857B (zh) | 一种提高l-异亮氨酸产率的发酵方法 | |
CN117844838A (zh) | 一株高产l-苯丙氨酸的菌株构建及其应用 | |
CN117721087A (zh) | 一种异丁香酚单加氧酶突变体及制备方法与应用 | |
CN117384813A (zh) | 依克多因合成菌株及其构建方法和应用 | |
CN114085801B (zh) | 一株生产l-色氨酸的重组大肠杆菌及其应用 | |
CN116355818A (zh) | 一种生产l-亮氨酸的基因工程菌及其应用 | |
CN115125278A (zh) | 一种生产聚唾液酸用的补料液及聚唾液酸制备方法 | |
CN112852773B (zh) | 一种发酵生产d-氨基酸氧化酶的方法 | |
CN115181684A (zh) | 一种mk-7的发酵培养基 | |
CN116286575B (zh) | 一种利用枯草芽孢杆菌高效表达生淀粉α-淀粉酶的方法 | |
CN112481186B (zh) | 一种生产4-羟基异亮氨酸的基因工程菌及其应用 | |
CN117417952B (zh) | 一种提高香兰素产量的重组拟无枝酸菌、其构建方法及应用 | |
CN117925744B (zh) | 非核糖体肽合成酶在生产脱羧肌肽中的应用 | |
CN118726220A (zh) | 一种高产l-缬氨酸的谷氨酸棒杆菌重组菌及其构建方法 | |
CN118726218A (zh) | 一种重组谷氨酸棒杆菌及其以葡萄糖为原料发酵生产亚精胺的方法 | |
CN116445384A (zh) | 一种利用简单脱毒的玉米芯纤维素水解液发酵生产bt的方法 | |
CN117487732A (zh) | 一种无质粒无缺陷型l-亮氨酸生产菌株的构建 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |